NCT00559702 - Safety Study of Natalizumab to Treat Multiple Sclerosis (MS) | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

October 31, 2007

Primary Completion Date

November 30, 2011

Study Completion Date

November 30, 2011

Conditions

Relapsing-Remitting Multiple SclerosisSecondary Progressive Multiple Sclerosis

Interventions

DRUG

natalizumab

OTHER

standard of care

standard of care as determined by the Investigator and Treating Neurologist

Trial Locations (12)

Research Site, Buffalo

Research Site, Vienna

Research Site, Maitland

Research Site, Vero Beach

Research Site, Farmington Hills

Research Site, Peoria

Research Site, Dallas

Research Site, Round Rock

Research Site, Centennial

Research Site, Phoenix

Research Site, Scottsdale

Research Site, Berkeley